How many insider trades does FilingIQ track for RDHL?

FilingIQ tracks 3 Form 4 insider transactions for RDHL (RedHill Biopharma Ltd.), covering filings from Apr 22, 2026 onwards. 2 of those are dated within the last 90 days.

Are RDHL insiders net buyers or net sellers?

Across the full Form 4 history for RDHL, 0 transactions (0%) were open-market purchases and 3 (100%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does RDHL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is RDHL in?

RedHill Biopharma Ltd. (RDHL) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $4.33M.

RDHL insider trading

NasdaqCM Healthcare

RedHill Biopharma Ltd.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 100%

Market cap

$4.33M

About RedHill Biopharma Ltd.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Company website: www.redhillbio.com

RDHL insider activity at a glance

FilingIQ tracks 3 insider transactions for RDHL in filings since Apr 22, 2026. The most recent transaction is dated Oct 1, 2026.

Across the full history, 0 open-market purchases and 3 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live RDHL trades on FilingIQ Raw filings on SEC EDGAR

Latest RDHL Form 4 filings

Raday Gilead Chief Operating Officer

SM Oct 6, 2026

Raday Gilead Chief Operating Officer

SM Jul 13, 2026

Raday Gilead Chief Operating Officer

SM Apr 22, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for RDHL?: FilingIQ tracks 3 Form 4 insider transactions for RDHL (RedHill Biopharma Ltd.), covering filings from Apr 22, 2026 onwards. 2 of those are dated within the last 90 days.
Are RDHL insiders net buyers or net sellers?: Across the full Form 4 history for RDHL, 0 transactions (0%) were open-market purchases and 3 (100%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does RDHL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is RDHL in?: RedHill Biopharma Ltd. (RDHL) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $4.33M.

Methodology & sources

Every RDHL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.